Long-term effect of rituximab in anti-mag polyneuropathy.
Benedetti
L
L
Department of Neurosciences, Ophthalmology and Genetics, University of Genova, Genova, Italy. luanabenedetti@libero.it
Briani
C
C
Franciotta
D
D
Carpo
M
M
Padua
L
L
Zara
G
G
Zambello
R
R
Sormani
M P
MP
Mancardi
G L
GL
Nobile-Orazio
E
E
Schenone
A
A
D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007075:Immunoglobulin M / Q000097:blood*; D007155:Immunologic Factors / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D018992:Myelin-Associated Glycoprotein / Q000276:immunology*; D011115:Polyneuropathies / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D000069283:Rituximab; D013997:Time Factors; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007075:Immunoglobulin M; D007155:Immunologic Factors; D018992:Myelin-Associated Glycoprotein; D000069283:Rituximab